How Has the Dermatitis Market Size Evolved in Recent Years?
The dermatitis market has seen considerable growth due to a variety of factors.
• In the past few years, we've witnessed a strong expansion in the dermatitis market. Its size is projected to increase from $6.77 billion in 2024 to $7.13 billion in 2025, an upward progression signified by a compound annual growth rate (CAGR) of 5.4%.
Factors that contributed to the growth during the historic period include a rise in prevalence, advancements in diagnostics, improvements in treatment options, and regulatory approvals.
What Is The Forecast For The Dermatitis Market Size?
The dermatitis market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipations are high for consistent expansion in the dermatitis market over the coming years. The projected value of this market by 2029 is estimated to be $8.66 billion, courtesy of a compound annual growth rate (CAGR) of 5.0%.
The surge during the forecast period can be correlated with heightened patient understanding and environmental elements. The major trends predicted for this time frame encompass research and development efforts, the rise of telemedicine and digital health, the implementation of biologics and targeted therapies, and the advent of personalized medicine.
What Are The Essential Drivers Behind The Growth Of The Dermatitis Market?
The primary factor propelling the growth of the dermatitis market is the surge in global instances of the condition. Dermatitis is theorized to affect approximately 15-20% of children and between 1-3% of adults. The escalating numbers of food allergies have also contributed to the increased incidences of dermatitis, consequently leading to a greater demand for curative medicines. For instance, the Global Atopic Dermatitis Atlas (GADA), a report by the International Eczema Council (IEC) - a dermatology association based in the US - had reported in October 2022 that almost 223 million people were affected by atopic dermatitis in that year. A significant portion of this total, about 43 million, were children aged between 1 and 4 years.
How Is The Global Dermatitis Market Divided Into Key Segments?
The dermatitis market covered in this report is segmented –
1) By Drug Class: Corticosteroids, Emollients Or Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors
2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online Or Mail Pharmacies
3) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Emollients Or Moisturizers: Creams, Ointments, Lotions, Gels, Other Emollients Or Moisturizers
3) By Antihistamines: Oral Antihistamines, Topical Antihistamines, Injectable Antihistamines
4) By Calcineurin Inhibitors: Topical Calcineurin Inhibitors (Tacrolimus, Pimecrolimus), Oral Calcineurin Inhibitors
5) By Antibiotics: Topical Antibiotics, Oral Antibiotics, Systemic Antibiotics
6) By Immunomodulators: Topical Immunomodulators, Oral Immunomodulators
7) By Interleukin Inhibitors: IL-4 Inhibitors, IL-13 Inhibitors, IL-31 Inhibitors, Other Interleukin Inhibitors
Pre-Book The Dermatitis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Dermatitis Market?
An upward trend in mergers and acquisitions (M&A) has been observed in the dermatitis marketplace, with companies engaging in these activities for the purpose of broadening their businesses and enhancing their visibility. M&As are currently having a substantial impact and are expected to drive market growth in the looming years. The market participants are concentrating their efforts on collaborations and partnerships to enrich their product offerings and gain substantial market dominance. Business strategies are inclusive of M&As to diminish competition and enhance their business scalability. An example of this occurred in March 2022 when Pfizer Inc., a pharmaceutical manufacturer based in the US, took over Arena Pharmaceuticals, Inc. for a confidential sum. This move is intended to help Pfizer bolster its arsenal of therapeutic treatments under various stages of development in the domains of gastroenterology, dermatology, and cardiology. Arena Pharmaceuticals, Inc. is a clinical-stage firm based in the US, known for developing treatments for dermatological diseases like atopic dermatitis (AD).
Who Are the Key Players In The Dermatitis Market?
Major companies operating in the dermatitis market include:
• LEO Pharma AS
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.
• Bayer AG
• Encore Dermatology Inc.
• Meda Pharmaceuticals Inc.
• Allergan Plc
• Bristol-Myers Squibb Co.
• Anacor Pharmaceutical Inc.
• Astellas Pharma Inc.
• Mylan N.V.
• Valeant Pharmaceutical Inc.
• Galderma SA
• Dow Inc.
• Connetics Corporation
• Fujisawa Pharmaceutical Company Ltd.
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Valeant Pharmaceuticals International Inc,
• GlaxoSmithKline plc
• Medimmune Inc.
• Bausch Health Co. Inc.
• Nestlé Skin Health India Pvt. Ltd.
• Aqua Pharmaceuticals Pvt. Ltd.
• C.H. Boehringer Sohn AG & Co. KG
• Biofrontera AG
• Zydus Lifesciences Limited
What Are The Regional Insights Into The Dermatitis Market?
North America was the largest region in the dermatitis market in 2023. Middle East is expected to be the fastest-growing region in the dermatitis market report during the forecast period. The regions covered in the dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
